KK Kose header image

KK Kose

4922

Equity

ISIN JP3283650004 / Valor 1017515

Tokyo Stock Exchange (2024-09-18)
JPY 7,930.00-0.88%

KK Kose
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

KK Kose is a company that specializes in providing solutions aimed at optimizing the prospecting process for sales professionals. By offering tools that streamline the identification and engagement of potential leads, KK Kose positions itself as a valuable asset for individuals and organizations looking to enhance the efficiency and effectiveness of their sales strategies. The company's services are designed to reduce the time spent on prospecting, as highlighted by a user's testimonial comparing it favorably to ZoomInfo, suggesting a significant time saving of approximately 10 hours a week. This indicates that KK Kose's offerings not only focus on lead generation but also on improving the quality of leads, thereby enabling more personalized and targeted prospecting approaches.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (07.08.2024):

Net Sales Growth

In the first quarter of 2024, KK Kose reported consolidated net sales of 77,583 million yen, marking a 13.8% increase compared to the same period in 2023. This growth was driven by strong sales in Japan across all segments and robust performance at Tarte, which primarily operates in the United States and Europe.

Operating Profit Increase

KK Kose's operating profit for the first quarter of 2024 rose significantly by 35.5% year-over-year, reaching 7,902 million yen. This increase was attributed to higher sales in Japan and at Tarte, along with reductions in the cost of sales ratio and SG&A expense ratio.

Ordinary Profit Surge

Ordinary profit for KK Kose in the first quarter of 2024 surged by 54.1% to 10,282 million yen. The substantial rise was primarily due to an increase in foreign exchange gains, which positively impacted the overall profitability of the company.

Profit Attributable to Owners

KK Kose reported a 78.1% increase in profit attributable to owners of the parent company for the first quarter of 2024, amounting to 6,943 million yen. This significant growth was driven by strong domestic sales and improved profitability at Tarte, despite lower sales in the China travel retail sector.

Dividend Forecast

KK Kose has maintained its dividend forecast for the fiscal year ending December 31, 2024. The company plans to distribute a total annual dividend of 140.00 yen per share, with an interim dividend of 70.00 yen and a year-end dividend of 70.00 yen, reflecting confidence in its financial stability and future outlook.

Summarized from source with an LLMView Source

Key figures

-33.2%1Y
-39.6%3Y
-58.4%5Y

Performance

41.5%1Y
38.5%3Y
37.1%5Y

Volatility

Market cap

3403 M

Market cap (USD)

Daily traded volume (Shares)

183,700

Daily traded volume (Shares)

1 day high/low

8061 / 7857

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

ModivCare Inc
ModivCare Inc ModivCare Inc Valor: 59168951
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.30%USD 13.50
Novo Nordisk A/S
Novo Nordisk A/S Novo Nordisk A/S Valor: 129508879
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.35%DKK 882.20
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC Valor: 2324471
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.05%GBP 19.14
CureVac N.V.
CureVac N.V. CureVac N.V. Valor: 56537572
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.30%USD 3.29
InMode Ltd.
InMode Ltd. InMode Ltd. Valor: 49023508
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.52%USD 17.46
Glaukos Corp
Glaukos Corp Glaukos Corp Valor: 28262610
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.60%USD 122.31
Allogene Therapeutics Inc
Allogene Therapeutics Inc Allogene Therapeutics Inc Valor: 43756548
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%USD 2.88
DocMorris Ltd
DocMorris Ltd DocMorris Ltd Valor: 4261528
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.26%CHF 35.26
SHL Telemedicine Ltd
SHL Telemedicine Ltd SHL Telemedicine Ltd Valor: 1128957
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
8.42%CHF 3.09
Dr Reddy'S Laboratories Ltd
Dr Reddy'S Laboratories Ltd Dr Reddy'S Laboratories Ltd Valor: 1221723
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.93%USD 78.79